The US Food and Drug Administration recently approved the first new antibiotics to treat urinary tract infections for about three decades.
UTIs are infected in each part of the urinary system and affect 16 million American women annually. One out of every four women is affected by UTI throughout their lives, and approximately 30 % are susceptible to repeated painful infections.
Blujepa, built by the British GSK PLC, for the treatment of women and children at the age of 12 with undeniable bacteria such as E. COLI, Klebsiella Pneumoniae, Citrobacter FreunDii, Enterococcus Faecalis, and a staph staph staph staph -staphococcus infection.
“Blujepa’s approval is an important turning point with uutis among the most common infections in women,” said Tony Wood, a senior scientific officer in GSK.
“We are proud to have developed Blujepa, for the first time in a new class of oral antibiotics for Uutis for nearly three decades and provides another option for patients due to repeated infections and increased resistance to existing treatments,” he said.
This confirmation is based on the results of a two -phase III clinical trial of 3,000 adolescents and adolescents. Phase III experiments If treatment is better than what is currently available.
GSK said these trials show “lack of interest in” nitrofuraniaine, which is an antibiotic approved to treat UTIS decades ago.
It was shown that Blujepa successfully treats between 50 and 58 percent of infections when taking twice a day for five days. This percentage is compared to participants who received nitrophortoid with 43 % to 47 %.
In both therapeutic methods, in both tests, there was a serious drug -related side effect. In Blujepa, the most common reported side effects were diarrhea and nausea.
The business set up antibiotics in the United States is scheduled in the second half of 2025.
GSK says new treatments are needed by increasing the number of UTIs caused by drug -resistant bacteria.
There are three main types of UTI that affect the urethra, bladder and kidney. Bladder infection can lead to pain during urination, blood in the urine, cramps and frequent urination. Kidney infection can lead to fever, chills, low back pain and vomiting.
If the UTI is complicated, regular treatment with antibiotics is not enough to treat it. This can lead to permanent kidney damage.
UTIs are more common in women because their urethra is closer to their intestines and makes it easier to enter the bacteria to enter the urinary tract. Risk factors change over time, with the most common pre -menopausal factors, including sexual intercourse and the use of chemical -based income control. After menopause, Harvard Medical School says physical changes will help determine the infection stage.
Women can prevent infection by urinating after sex, hydrating and taking a shower instead of the bathroom.
“For many, the UTI can be heavy on everyday life,” said Dr. Thomas Hutten, a clinical medicine professor at the University of Miami Medical School. “With the increasing number of patients who experience recurrent infections, there is a need for continuous research on antimicrobials to help address the patient’s constant challenges and pressure in health care systems.”
